While adult patients with AML showed a higher burden of adverse-risk mutations, including FLT3-ITD, TP53 mutations, and complex karyotypes, these were linked to increased relapse and reduced overall survival post-HSCT (37). Here, TP53 is linked to acute myeloid leukemia.